ArticleCardiovascular diagnosis and therapy2019
Antibody to oxidized low-density lipoprotein inhibits THP1 cells from apoptosis by suppressing NF-κB pathway activation.
Article in Cardiovascular diagnosis and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- LITAF Promotes Atherosclerotic Plaque Formation by Stimulating the NF-κB Inflammatory Pathway.Current medical science · 2023Article
- Positive Association between Autoantibodies Against Oxidized LDL and HDL-C: A Novel Mechanism for HDL Cardioprotection?Arquivos brasileiros de cardiologia · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate whether the oxidized low-density lipoprotein (Ox-LDL) antibody is able to inhibit THP1 cell apoptosis by suppressing NF-κB pathway.
methodsTHP1 cells were induced to macrophages with phorbol 12-myristate 13-acetate (PMA). Macrophages were divided into control group, Ox-LDL group and antibody group, cells in which were treated with phosphate buffered saline (PBS), Ox-LDL (50 mg/mL), Ox-LDL (50 µg/mL) plus Ox-LDL antibody (100 mg/L), respectively, for 24 h. The apoptosis rate was determined by inverted microscopy and flow cytometry. The protein and mRNA expression of NF-κB (P65), caspase-3 and BCL2 was detected by Western blotting and reverse transcription polymerase chain reaction (RT-PCR), respectively.
resultsThe apoptosis rate reduced significantly in antibody group as compared to Ox-LDL and control groups (P<0.05). The protein and mRNA expression of NF-κB pathway was markedly lowered in antibody group than in Ox-LDL and control groups (P<0.05), which reduced the Ox-LDL induced inflammation.
conclusionsOx-LDL antibody may be used to attenuate Ox-LDL induced inflammation and apoptosis, preventing atherosclerosis patients from acute coronary syndrome (ACS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.